Piper Sandler Reiterates Overweight on DexCom, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has reiterated an Overweight rating on DexCom (NASDAQ:DXCM) and maintained a price target of $90.
August 26, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Matt O'Brien has reiterated an Overweight rating on DexCom, maintaining a price target of $90. This suggests confidence in DexCom's stock performance.
The reiteration of an Overweight rating and maintenance of a $90 price target by Piper Sandler indicates a positive outlook on DexCom's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100